There were 324 press releases posted in the last 24 hours and 153,409 in the last 365 days.

Guatemala Programme Doubles Diagnosis of Fatal Fungal Infections in AIDS

Professor Juan Luis Rodriguez Tudela

“For less than $100 per tested patient, the ASI and the HIV units in Guatemala have shown that a new paradigm of care for advanced HIV disease is possible.”
— Professor Juan Luis Rodriguez Tudela
GUATEMALA CITY, GUATEMALA, March 13, 2018 / -- GAFFI’s program to reduce deaths from fungal diseases with HIV in Guatemala in 2017 shows that at least 55% of serious infections in AIDS are fungal, dwarfing tuberculosis. Over 2,000 HIV patients were tested from across the country and 371 (16%) had a life-threatening infection that is always fatal without therapy. The diagnostic and training was undertaken locally by the Asociación de Salud Integral (ASI) in Guatemala City.

In 2016, GAFFI started to implement a new integrated model of advanced HIV care in Guatemala with the objectives of educating Health Professionals (partly delivered online through, more rapid diagnosis of fungal disease and TB, and sourcing affordable medications for treatment. A network of 13 HIV units were clinically trained and then delivered samples by courier to the ASI central reference laboratory, using online requests. In 2017 enhanced coordination of the network was achieved with improved recording of all clinical samples and patient data into a central facility (through a website); faster Reference Laboratory workflow was targeted to increase turnaround time of samples (most within 24-72 hours).

In fact, 2,494 patients were tested in 2017, of which 371 (16%) had an opportunistic infection, 55% of which were fungal, the remainder tuberculosis.

Disseminated histoplasmosis was diagnosed in 141 patients (38%), cryptococcal infections in 84 (22.6%) and other fungal infections in 3 (0.8%). 157 (42.3%) cases of M. tuberculosis and other mycobacterial infections were also diagnosed. Fifteen dual infections were detected, 10 (2.7%) of coinfection with M. tuberculosis and Histoplasma capsulatum, which are particularly challenging to treat.

In comparison with 2016, prior to the network being implemented, we observed a 111% increase in the diagnosis of opportunistic infections - a rise of 176 to 371 cases. Importantly, the network ruled out these potentially fatal infections in 2123 HIV cases, allowing an earlier start of antiretroviral therapy and therefore the chance of a better outcome for the patient.

Professor Juan Luis Rodriguez Tudela, from GAFFI, said: “For less than $100 per tested patient, the ASI and the HIV units in Guatemala have shown that a new paradigm of care for advanced HIV disease is possible. Clinicians are empowered, patients are treated correctly without wastage and additional drug toxicities, and we suspect lives are being saved.”

In 2018, molecular diagnosis of Pneumocystis pneumonia and antibody testing for aspergillosis will be implemented to give a fuller picture of fungal infections in AIDS, and provide additional treatment or discontinuation of empirical treatment options. Assessment of clinical outcomes is ongoing, as an estimated 1,600 died of AIDS in 2016, a high proportion of the 46,000 HIV-infected people. In Guatemala, only 36% of these HIV-infected people are on antiretroviral therapy.

Link to Guatemala report


GAFFI is a registered International Foundation based in Geneva and UK Charity and is focused on 4 major tasks related to serious fungal infections. These are:

• Universal access to diagnostics for serious fungal disease

• Universal access to antifungal agents
• Accurate data on the number and severity of fungal infections
• Health professional education related to better recognition and care for patients with serious fungal disease

GAFFI issued its 10 year Roadmap ’95-95 by 2025’ in 2015 calling on all governments and international health agencies to ensure 95% of the global population have access to fungal diagnostics and antifungal therapies by 2025: GAFFI has enabled several antifungal drugs to be listed on the World Health Organisation’s Essential Medicine List, including those used for aspergillosis.

Luisa Morlano
The Goodwork Organisation Ltd
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.